Pimitespib
Code | Size | Price |
---|
TAR-T16994-5mg | 5mg | £125.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T16994-1mL | 1 mL * 10 mM (in DMSO) | £131.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T16994-10mg | 10mg | £148.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T16994-25mg | 25mg | £230.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T16994-50mg | 50mg | £374.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
TAS-116 is an ATP-competitive and highly specific HSP90α/HSP90β inhibitor (Kis: 34.7 nM and 21.3 nM, respectively).
CAS:
1260533-36-5
Formula:
C25H26N8O
Molecular Weight:
454.538
Pathway:
Metabolism; Cytoskeletal Signaling
Purity:
0.9949
SMILES:
CCc1cc(ccc1-n1nc(C(C)C)c2c(ccnc12)-n1cnc(c1)-c1cnn(C)c1)C(N)=O
Target:
HSP
References
1. Ohkubo S, et al. TAS-116, a highly selective inhibitor of heat shock protein 90? and ?, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models. Mol Cancer Ther. 2015 Jan;14(1):14-22.
2. Suzuki R, et al. Anti-tumor activities of selective HSP90?/? inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. Leukemia. 2015 Feb;29(2):510-4.
3. Utsugi T. New challenges and inspired answers for anticancer drug discovery and development. Jpn J Clin Oncol. 2013 Oct;43(10):945-53.